Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KIF5B | P33176 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365368 | 1.00 | KDM4E (0.42) | KDM4ETDP1EGFRRETKIF5B | |
| SCHEMBL17070605 | 1.00 | KDM4E (0.42) | KDM4ETDP1EGFRRETKIF5B | |
| SCHEMBL7110169 | 0.98 | KDM4E (0.41) | KDM4ETDP1EGFRRETKIF5B | |
| SCHEMBL30572965 | 0.86 | CD274 (0.44) | NPC1HTT | |
| SCHEMBL29677789 | 0.82 | HTT (0.50) | KDM4ETDP1EGFRRETKIF5B | |
| SCHEMBL282059 | 0.82 | HTT (0.50) | KDM4ETDP1EGFRRETKIF5B | |
| SCHEMBL7572203 | 0.81 | MAPK1 (0.52) | TDP1HTTLMNA | |
| SCHEMBL25355053 | 0.81 | MAPT (0.42) | TDP1EGFRKDRHTTTUBB4A | |
| SCHEMBL7108662 | 0.80 | HTT (0.48) | KDM4ETDP1EGFRRETKIF5B | |
| SCHEMBL27164750 | 0.79 | BRD4 (0.43) | KDM4ETDP1EGFRRETKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108623561-B | Method for preparing panenonic acid compound | 中国海洋大学 | 2025-04-01 | — | — | CN | claimed |
| CN-108623581-B | Method for preparing paninula compound | 中国海洋大学 | 2021-10-22 | — | — | CN | claimed |
| CN-108623581-A | A method of preparing piperazine Nino peace compound | 中国海洋大学 | 2018-10-09 | — | — | CN | claimed |
| CN-108623561-A | A method of preparing piperazine Nino acid compound | 中国海洋大学 | 2018-10-09 | — | — | CN | claimed |
| US-20090233930-A9 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| EP-1979324-A2 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA | Astra Zeneca AB (SE) | 2008-10-15 | — | — | EP | claimed |
| WO-2007058602-A2 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA. | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | claimed |
| EP-4747241-A1 | BENZIMIDAZOLE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4634178-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| EP-4634162-A1 | BENZIMIDAZOLE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-12390462-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-0175452-A1 | 1,3-Disubstituted piperidine compounds as neuroleptic agents | PFIZER INC. (US) | 1986-03-26 | — | — | EP | disclosed |
| US-4556676-A | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0028901-B1 | ANTIDEPRESSANT DERIVATIVES OF TRANS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0030081-B1 | ANTIDEPRESSANT DERIVATIVES OF CIS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0030081-A1 | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-06-10 | — | — | EP | disclosed |
| EP-0028901-A1 | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233930-A9 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | PSEN2, MAPT, PSEN1 | KDM4E 1426/4885TDP1 131/4885EGFR 2283/4885 |
| US-12390462-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | KDM4E 2921/4885TDP1 1551/4885EGFR 2097/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | KDM4E 1128/4885TDP1 1782/4885EGFR 4367/4885 |
| US-20080293718-A1 | Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia | PSEN2, MAPT, PSEN1 | KDM4E 1426/4885TDP1 131/4885EGFR 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.